Introducing Credence Tumor Hotspots

Even though a group of patients may show similar symptoms at the onset of a disease, their response to the prescribed (similar) drug vary depending on their genetic components, thus some may recover while others may remain sick or even develop adverse side effects.  Therefore, personalized medicine is the new era of medical treatment where each prescribed drug is tailored to best-fit the genetic conditions of the individual. Credence Tumor Hotspots is specifically designed to study the genetic basis of cancer, aiming to help physicians in decision making process in cancer treatment.  This test determines the genetic components of cancers and is capable of testing 50 different genes for changes that might occur within it (mutations) leading to cancer onset.

How we can reduce the burden of disease

In the long run, Credence Tumor Hotspots seeks to reduce the burden of disease by targeting prevention and treatment more effectively.   With the help of tailored medical treatment, the health care management paradigm will focus on prevention, moving from illness to wellness, and from treating disease to maintaining health.  At the same time, it will reduce healthcare costs by improving the physicians’ ability to quickly and reliably select effective therapy for a given patient while minimizing costs associated with ineffective treatment and avoidable adverse effects.

Benefits of Credence Tumor Hotspots test include:

  • Detailed information on the molecular basis of each patient’s cancer
  • Indicates whether the patient is responding to current treatment or not
  • Helps physicians to efficiently prescribe the drugs to match the genetic composition of each patient
  • Maximizes the therapeutic outcome and increases the survival rate of patients affected by cancer
  • Minimizes adverse side effects of drugs

Personalized medicine

Personalized medicine makes use of molecular profiling techniques (genetic tests etc.) and a specific set of biomarkers (molecules that helps in tagging a biological process for better understanding and clear observation) to understand the genetic make-up of individuals.

tumor151114

Credence Tumor Hotspots panel

Credence Tumor Hotspots panel simultaneously screens 50 genes that are responsible for inherited predisposition to Tumor hotspots.  The genes covered in the panel include;

ABL1, EZH2, JAK3, PTEN, AKT1, FBXW7, IDH2, PTPN11, ALK, FGFR1, KDR, RB1, APC, FGFR2, KIT, RET, ATM, FGFR3, KRAS, SMAD4, BRAF, FLT3, MET, SMARCB1, CDH1, GNA11, MLH1, SMO, CDKN2A, GNAS, MPL, SRC, CSF1R, GNAQ, NOTCH1, STK11, CTNNB1, HNF1A, NPM1, TP53, EGFR, HRAS, NRAS, VHL, ERBB2, IDH1, PDGFRA, ERBB4, JAK2 and PIK3CA

Key points

  • Get the benefit of the most effective personalised medication with least side effects
  • Fastest possible recovery time
  • Understand all available prevention methodologies
  • Minimise the trauma of cancer
  • Benefit from early diagnosis and reduced medical costs

Did you know?

Medical diagnosis and treatment is now drifting away from trial and error based standard medicine (where all patients with similar category of symptoms are prescribed with a single drug – one size fits all approach) to more efficacious, cost effective, personalized treatments with no side effects.